What proportion of gastric ulcers are malignant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Malignancy Rate in Gastric Ulcers

Approximately 6-12% of gastric ulcers are malignant, with the vast majority (93%) identified on initial biopsy at the time of first endoscopy.

Current Evidence on Malignancy Prevalence

The malignancy rate in gastric ulcers varies based on population and study methodology:

  • Most recent high-quality data shows 6-12% malignancy rate: A 2024 study found 12% of gastric ulcers were malignant 1, while a 2016 UK cohort demonstrated 6% malignancy 2, and a 2022 Australian study reported 7% 3.

  • Historical data showed higher rates: An older 1980 study reported 14% malignancy 4, though this likely reflects differences in diagnostic techniques and population characteristics.

  • Geographic variation exists: Studies from high gastric cancer prevalence regions may show different rates, with a 2016 Korean study also finding approximately 6% malignancy 5.

Critical Timing of Malignancy Detection

The overwhelming majority of malignant gastric ulcers are identified at initial endoscopy, not on surveillance:

  • 93% of malignancies are diagnosed on first biopsy 2
  • 83% of cancers identified at initial gastroscopy 3
  • The yield of surveillance endoscopy after benign initial histology is extremely low at 0.9-2% 3, 2

Endoscopic Features Predicting Malignancy

Specific endoscopic characteristics strongly predict malignancy and should guide biopsy strategy:

  • Irregular border (AUROC 0.89) is the strongest single predictor 1
  • Elevated border (AUROC 0.84) 1
  • Gastric atrophy on histopathology (AUROC 0.87) 1
  • Corpus or cardia location 1
  • Large ulcer size (>1 cm diameter) 4

A multivariate model combining corpus/cardia location, irregular border, elevated border, and gastric atrophy achieved excellent discrimination (AUROC 0.96) with only 0.4% false negatives 1.

Clinical Implications for Practice

All gastric ulcers must be biopsied at initial endoscopy 2. The British Society of Gastroenterology guidelines emphasize that the miss rate for gastric cancer on endoscopy is high, highlighting the importance of adequate initial biopsy 6.

Surveillance endoscopy may be unnecessary in specific low-risk scenarios:

  • Endoscopically benign appearance (OR 0.004 for malignancy) 2
  • Benign histology on first biopsy (OR 0.12 for malignancy) 1
  • Complete healing on repeat endoscopy (OR 0.5 for malignancy) 3

However, surveillance remains warranted when:

  • Endoscopic features suggest malignancy (irregular/elevated borders) 1, 5
  • Initial biopsy shows atypia or dysplasia 5
  • Inadequate initial biopsy sampling 2

Common Pitfalls

The 2002 dyspepsia guidelines note that endoscopy should be performed when symptoms are present and after a minimum of one month off antisecretory therapy to avoid missing lesions 6. Visual inspection alone tends to over-diagnose malignancy, making histologic confirmation essential 4.

References

Research

Clinical outcomes of endoscopic surveillance for gastric ulcers in populations with a high prevalence of gastric cancer.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.